How many ml in lantus solostar pen

Other interactions can increase side effects or make them more severe. Below are lists of medications that can interact with Lantus. Before taking Lantus, talk with your doctor and pharmacist. Tell them about all prescription, over-the-counter, and other drugs you take. Also tell them about any vitamins, herbs, and supplements you use. Sharing this information can help you avoid potential interactions. If you have questions about drug interactions that may affect you, ask your doctor or pharmacist.

Taking Lantus with other diabetes medications can increase your risk for hypoglycemia low blood sugar level. If you take Lantus with other diabetes drugs, your doctor may need to adjust your dosage of one or all of them to reduce your risk for low blood sugar.

They may also want you to monitor your blood sugar levels more often. Examples of other diabetes medications that can increase your risk for low blood sugar if taken with Lantus include:. Taking Lantus with thiazolidinediones can cause heart failure , or worsen heart failure if you already have it. If you take a thiazolidinedione, be sure to discuss it with your doctor before you start treatment with Lantus.

If you take one of these drugs with Lantus, your doctor will likely monitor you for signs of heart failure. Taking Lantus with certain blood pressure medications can increase your risk for hypoglycemia low blood sugar level. If you take Lantus with one of these drugs, your doctor may need to adjust the dosage of either Lantus or the blood pressure medication.

Examples of blood pressure medications that can increase your risk for low blood sugar if taken with Lantus include:. Taking Lantus with other types of blood pressure medications can hide the symptoms of low blood sugar when they occur.

This can put you at risk for severe hypoglycemia very low blood sugar level with little warning. If you take Lantus with any of these drugs, your doctor may want you to check your blood sugar levels more often. Taking Lantus with certain antipsychotics can decrease how well Lantus works. This can lead to high blood sugar levels and an increased risk of complications from diabetes.

They may also recommend that you check your blood sugar levels more often. Taking Lantus with corticosteroids can decrease how well Lantus works. This could increase your blood sugar levels, leading to a higher risk of serious complications, such as heart disease. They will also advise you to check your blood sugar levels more often. However, drinking too much alcohol while taking Lantus can increase your risk for hypoglycemia low blood sugar levels.

This is because both alcohol and Lantus can lower blood sugar levels on their own. Lantus is classified as a long-acting insulin. It lowers blood sugar levels in people with type 1 or type 2 diabetes. Lantus is made to work like natural insulin in your body. Insulin is a hormone that does the following:. So you take medication, such as Lantus, to replace the insulin. Your pancreas may also stop making insulin, which would need to be replaced with medication. Lantus starts lowering blood sugar levels within a few hours.

Long-acting insulins take longer than short-acting insulins to start working. But they last longer in your body.

After you inject Lantus, the drug forms clusters beneath your skin. As these clusters break down, insulin is slowly released into your bloodstream throughout the hour period. The solution in the vial is injected using a syringe and needle. Your doctor will discuss whether the vial or SoloStar pen is right for you.

Whether you use a syringe or the Solostar pen, never reuse a needle or share a needle with another person. This helps prevent the spread of germs. Below is information on how to use the vial and syringe, and SoloStar pen. Lantus is given as an injection just under your skin a subcutaneous injection , once a day. When you first get your Lantus prescription, your healthcare provider will explain how to inject the medication yourself.

You can take Lantus at any time, but it should be at the same time each day. Ask your doctor what time is best for you. Many people take their Lantus dose at bedtime. However, according to the American Diabetes Association , insulin therapy such as Lantus is the first-choice option for diabetes treatment during pregnancy.

Insulin therapy is also recommended for women who developed diabetes while pregnant called gestational diabetes. If you need treatment to help control your blood sugar levels during pregnancy, talk with your doctor. This can help keep your blood sugar levels in a safe range for you and your baby. However, you may need a different dose of Lantus for a time after you give birth.

This is due to changes in your body and changes in your sleep and mealtime schedules. You may need a rapid-acting insulin , short-acting insulin, or intermediate-acting insulin to fine-tune your blood sugar level control. Many people who use a long-acting insulin such as Lantus will also need rapid-acting or short-acting insulin to control blood sugar levels after meals. This could change how well the insulins work. If you have any questions about when or how to take each type of insulin, talk with your doctor or pharmacist.

In clinical studies , blood sugar levels were reduced to a similar degree whether people took Lantus in the morning or evening. Your doctor will monitor how your blood sugar levels change throughout the day. It can. Hypoglycemia low blood sugar levels is one of the most common side effects of insulin products, including Lantus. Also, making any changes to your insulin treatment plan could increase your risk for both hypoglycemia and hyperglycemia high blood sugar levels.

Severe hypoglycemia very low blood sugar level can be life-threatening if not treated right away. Talk with your doctor or pharmacist about creating a plan to prevent and manage low blood sugar levels. DKA is a serious complication of diabetes. It occurs when your blood sugar levels are very high but your insulin levels are low. Instead, your body starts breaking down fat into ketones a certain type of protein for energy.

High levels of ketones make your blood more acidic, which can harm many organs in your body. DKA treatment takes place in a hospital setting. Treatment involves using insulin to bring sugar into your cells. Faster-acting insulins such as insulin aspart Fiasp, Novolog , insulin glulisine Apidra , or insulin lispro Admelog, Humalog are typically used as part of DKA treatment.

Before taking Lantus, talk with your doctor about your health history. Lantus may not be right for you if you have certain medical conditions. These include:. When you get Lantus from the pharmacy, the pharmacist will add an expiration date to the label on the bottle.

This date is typically one year from the date they dispensed the medication. The expiration date helps guarantee the effectiveness of the medication during this time. If you have unused medication that has gone past the expiration date, talk to your pharmacist about whether you might still be able to use it.

How long a medication remains good can depend on many factors, including how and where you store the medication. You should store unopened Lantus vials in your refrigerator until the expiration date listed on the package. Once you open a Lantus vial, you can store it at room temperature or in the refrigerator for 28 days.

You can store unopened Lantus SoloStar pens in the refrigerator until the expiration date listed on the package. You can also store them for 28 days at room temperature. You should store unopened Lantus SoloStar pens in the refrigerator until the expiration date listed on the package. You should never freeze Lantus vials and SoloStar pens.

Also, keep them out of direct heat and light. Put it in a hard container, such as a sharps disposal container. You can get an FDA-approved sharps container at your pharmacy, through medical supply companies, or online.

Examples of containers that you can use include metal coffee cans and used laundry detergent bottles. Put a label on the container to warn people that there are needles inside. Be sure to keep a lid on the container at all times and store it away from children and pets.

This helps prevent others, including children and pets, from taking the drug by accident. It also helps keep the drug from harming the environment. The FDA website provides several useful tips on medication disposal. You can also ask your pharmacist for information on how to dispose of your medication. Lantus insulin glargine is indicated to improve blood glucose control in adults and children with type 1 diabetes and in adults with type 2 diabetes.

Lantus is a long-acting analog of human insulin engineered to be less soluble at physiological pH, causing crystallization at the injection site, a delay in absorption, and prolongation of action. Lantus exerts its hypoglycemic effects by increasing peripheral glucose uptake and inhibiting hepatic gluconeogenesis.

It also prevents fat and protein degradation while stimulating protein synthesis. Following subcutaneous injection, absorption of Lantus is relatively constant over a hour period.

Due to the consistency of insulin glargine, it does not have a defined half-life or peak. There is no peak concentration, as the release in the body remains constant. Lantus is partly metabolized in the subcutaneous depot to two active metabolites, which have similar activity to human insulin. Median time to end of pharmacological effect is 24 hours. Lantus is contraindicated for use during hypoglycemic episodes. Unopened Lantus vials and SoloStar pens should be stored at room temperature Opened pens should be stored at room temperature for 28 days.

Opened pens should not be refrigerated. Disclaimer : Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication.

The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.

As with all insulin preparations, the glucose lowering effect time course of LANTUS may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see Clinical Pharmacology Other factors which may increase the risk of hypoglycemia include changes in meal pattern e.

Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations 8. Patients and caregivers must be educated to recognize and manage hypoglycemia.

Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.

Accidental mix-ups among insulin products, particularly between long-acting insulins and rapid-acting insulins, have been reported. To avoid medication errors between LANTUS and other insulins, instruct patients to always check the insulin label before each injection [see Adverse Reactions 6. Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including LANTUS.

If hypersensitivity reactions occur, discontinue LANTUS; treat per standard of care and monitor until symptoms and signs resolve [see Adverse Reactions 6.

LANTUS is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients [ see Contraindications 4 ].

All insulin products, including LANTUS, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia, if indicated e. Thiazolidinediones TZDs , which are peroxisome proliferator-activated receptor PPAR -gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin.

Fluid retention may lead to or exacerbate heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The type 1 diabetes population had the following characteristics: Mean age was Fifty-four percent were male, The mean BMI was The type 2 diabetes population had the following characteristics: Mean age was Fifty-eight percent were male, The frequencies of adverse events during LANTUS clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in the tables below.

In the pediatric phase 3 clinical trial, children and adolescents with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia in the two treatment groups compared to the adult trials with type 1 diabetes. Some patients taking LANTUS have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Administration of insulin subcutaneously, including LANTUS, has resulted in lipoatrophy depression in the skin or lipohypertrophy enlargement or thickening of tissue in some patients [see Dosage and Administration 2. Insulin Initiation and Intensification of Glucose Control. Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy.

However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy. Weight gain has occurred with some insulin therapies including LANTUS and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.

As with any insulin therapy, patients taking LANTUS may experience injection site reactions, including redness, pain, itching, urticaria, edema, and inflammation. In clinical studies in adult patients, there was a higher incidence of treatment-emergent injection site pain in LANTUS-treated patients 2. The reports of pain at the injection site did not result in discontinuation of therapy. Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock may occur with any insulin, including LANTUS and may be life threatening.

As with all therapeutic proteins, there is potential for immunogenicity. All insulin products can elicit the formation of insulin antibodies. The presence of such insulin antibodies may increase or decrease the efficacy of insulin and may require adjustment of the insulin dose. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Medication errors have been reported in which other insulins, particularly rapid-acting insulins, have been accidentally administered instead of LANTUS [see Patient Counseling Information 17 ]. To avoid medication errors between LANTUS and other insulins, patients should be instructed to always verify the insulin label before each injection. Localized cutaneous amyloidosis at the injection site has occurred.

Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site. Published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes [see Data ]. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations ].

Rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0. Overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin [see Data ].

The estimated background risk of miscarriage for the indicated population is unknown. In the U. Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity. Published data do not report a clear association with insulin glargine and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine is used during pregnancy.

However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and some lacking comparator groups. Subcutaneous reproduction and teratology studies have been performed with insulin glargine and regular human insulin in rats and Himalayan rabbits.

Insulin glargine was given to female rats before mating, during mating, and throughout pregnancy at doses up to 0. In rabbits, doses of 0. The effects of insulin glargine did not generally differ from those observed with regular human insulin in rats or rabbits.

However, in rabbits, five fetuses from two litters of the high-dose group exhibited dilation of the cerebral ventricles. Fertility and early embryonic development appeared normal. There are either no or only limited data on the presence of insulin glargine in human milk, the effects on breastfed infant, or the effects on milk production. Endogenous insulin is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LANTUS, and any potential adverse effects on the breastfed child from LANTUS or from the underlying maternal condition.

The safety and effectiveness of LANTUS in pediatric patients younger than 6 years of age with type 1 diabetes and pediatric patients with type 2 diabetes have not been established. The dosage recommendation when changing to LANTUS in pediatric patients age 6 to 15 years with type 1 diabetes is the same as that described for adults [see Dosage and Administration 2. As in adults, the dosage of LANTUS must be individualized in pediatric patients age 6 to 15 years with type 1 diabetes based on metabolic needs and frequent monitoring of blood glucose.

In the pediatric clinical trial, pediatric patients age 6 to 15 years with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia compared to the adults in trials with type 1 diabetes [see Adverse Reactions 6. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. Hypoglycemia may be difficult to recognize in the elderly.

Some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure.

Excess insulin administration may cause hypoglycemia and hypokalemia [see Warnings and Precautions 5. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates.

Adjustments in drug dosage, meal patterns, or exercise may be needed. After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydrate intake may be necessary to avoid recurrence of hypoglycemia.

Hypokalemia must be corrected appropriately. Insulin glargine is a recombinant human insulin analog that is a long-acting, parenteral blood-glucose-lowering agent [see Clinical Pharmacology 12 ]. Insulin glargine has low aqueous solubility at neutral pH. At pH 4 insulin glargine is completely soluble. This profile allows once-daily dosing as a basal insulin. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.

Insulin glargine has the following structural formula:. The 10 mL vial presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2. The 3 mL prefilled pen presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.

Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis. In clinical studies, the glucose-lowering effect on a molar basis i. Figure 1 shows results from a study in patients with type 1 diabetes conducted for a maximum of 24 hours after the injection. The median time between injection and the end of pharmacological effect was The duration of action after abdominal, deltoid, or thigh subcutaneous administration was similar. A metabolism study in humans indicates that insulin glargine is partly metabolized at the carboxyl terminus of the B chain in the subcutaneous depot to form two active metabolites with in vitro activity similar to that of human insulin, M1 21 A -Gly-insulin and M2 21 A -Gly-des B -Thr-insulin.

Unchanged drug and these degradation products are also present in the circulation. In mice and rats, standard two-year carcinogenicity studies with insulin glargine were performed at doses up to 0.

Histiocytomas were found at injection sites in male rats and mice in acid vehicle containing groups and are considered a response to chronic tissue irritation and inflammation in rodents.

These tumors were not found in female animals, in saline control, or insulin comparator groups using a different vehicle. Insulin glargine was not mutagenic in tests for detection of gene mutations in bacteria and mammalian cells Ames and HGPRT-test and in tests for detection of chromosomal aberrations cytogenetics in vitro in V79 cells and in vivo in Chinese hamsters.

In a combined fertility and prenatal and postnatal study in male and female rats at subcutaneous doses up to 0. Consequently, a reduction of the rearing rate occurred in the high-dose group only. Similar effects were observed with NPH insulin. The safety and effectiveness of LANTUS given once-daily at bedtime was compared to that of once-daily and twice-daily NPH insulin in open-label, randomized, active-controlled, parallel studies of 2, adult patients and pediatric patients with type 1 diabetes mellitus and 1, adult patients with type 2 diabetes mellitus see Tables 9— Regular human insulin was administered before each meal.

NPH insulin was administered either as once daily at bedtime or in the morning and at bedtime when used twice daily. In Study A, the average age was The mean BMI was approximately The mean duration of diabetes was In Study B, the average age was The majority of patients were White Insulin lispro was used before each meal. The average age was Type 1 Diabetes — Pediatric see Table The mean duration of diabetes was 4. Regular human insulin was used before meals, as needed.

HbA1c change from baseline was a secondary endpoint. Similar glycemic control in the 2 treatment groups was desired in order to not confound the interpretation of the retinal data. The incidences of severe symptomatic hypoglycemia were similar between groups [see Adverse Reactions 6. Patients were also treated with insulin lispro at mealtime.

In these patients, data are available from 8-point home glucose monitoring. No patients in the other two arms discontinued for this reason. All patients in this study also received glimepiride 3 mg daily.

Retinopathy was evaluated in the LANTUS clinical studies by analysis of reported retinal adverse events and fundus photography. Mean baseline HbA1c was 8. Patients with prespecified postbaseline eye procedures pan-retinal photocoagulation for proliferative or severe nonproliferative diabetic retinopathy, local photocoagulation for new vessels, and vitrectomy for diabetic retinopathy were also considered as 3-step progressors regardless of actual change in ETDRS score from baseline.

Retinopathy graders were blinded to treatment group assignment. The results for the primary endpoint are shown in Table 13 for both the per-protocol and intent-to-treat populations, and indicate similarity of LANTUS to NPH in the progression of diabetic retinopathy as assessed by this outcome. The objective of the trial was to demonstrate that LANTUS use could significantly lower the risk of major cardiovascular outcomes compared to standard care.

The first coprimary endpoint was the time to first occurrence of a major adverse cardiovascular event defined as the composite of CV death, nonfatal myocardial infarction, and nonfatal stroke. The second coprimary endpoint was the time to the first occurrence of CV death or nonfatal myocardial infarction or nonfatal stroke or revascularization procedure or hospitalization for heart failure.

Anthropometric and disease characteristics were balanced at baseline. The mean HbA1c SD at baseline was 6. Vital status was available for The median duration of follow-up was 6. The mean HbA1c SD at the end of the trial was 6. The mean change in body weight from baseline to the last treatment visit was 2. Overall, the incidence of major adverse cardiovascular outcomes was similar between groups see Table All-cause mortality was also similar between groups. In the ORIGIN trial, the overall incidence of cancer all types combined or death from cancer Table 15 was similar between treatment groups.

Sharing carries a risk for transmission of blood-borne pathogens [see Warnings and Precautions 5. Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients of the symptoms of hypoglycemia.

Inform patients that the ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.

Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery [see Warnings and Precautions 5. Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision [see Warnings and Precautions 5.

Sharvik Impex India Private Limited. Lahar Pharmaceuticals. Lantus Solostar. Ozar Care Exim Private Limited. Lantus Solostar Ml Injection. Gallium Pharmaceuticals Private Limited. Lantus Solostar Injection, Sanofi. Lantus Solostar Pen, Liquid. Lantus Solostar Price. BETA These are indicative values based on popular product prices. Prices across cities for Lantus Solostar. Is the information useful? Lantus Solostar Pen is for use in adults with type 1 or type 2.

I agree to the terms and privacy policy. Lantus Solostar Pen is used to improve blood sugar control in people with diabetes mellitus. Jawa Pharmacy Amravati P. Have a Question? Ask our expert. Speak your question. It provides a steady level of insulin. Lantus Solostar Get Quote.